Anthony Pozun, DO
Interventional Cardiology · Glendale, AZNPI 1275580755
Payments from drug & device makers
Across 378 payments — averaging $262.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$78K
- Medtronic$9K
- Abbott$3K
- Penumbra, Inc.$3K
- Cvrx, Inc.$1K
- Boston Scientific$977
- plus $4K from 33 others
What the payments were for
- Travel & lodging$9,3769%
- Food & beverage$12,39912%
- Education$10,80011%
- Other$66,79267%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 32 | $78,025 |
| Medtronic(2 entities) | 52 | $8,929 |
| Abbott | 46 | $3,146 |
| Penumbra, Inc. | 9 | $2,802 |
| Cvrx, Inc. | 25 | $1,102 |
| Boston Scientific | 41 | $977 |
| Amgen | 25 | $634 |
| Johnson & Johnson | 19 | $388 |
| E.r. Squibb & Sons, L.L.C. | 10 | $383 |
| Novartis | 12 | $330 |
| Avinger Inc. | 6 | $309 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $256 |
| Biosense Webster, Inc. | 2 | $223 |
| Novo Nordisk | 5 | $195 |
| Actelion Pharmaceuticals US, Inc. | 5 | $194 |
| Cardiovascular Systems Inc. | 7 | $158 |
| Tactile Systems Technology Inc | 6 | $153 |
| Bardy Diagnostics, Inc. | 8 | $125 |
| Nipro Medical Corporation | 4 | $124 |
| Cordis US CORP. | 1 | $110 |
| Regeneron Healthcare Solutions, Inc. | 7 | $100 |
| Kestra Medical Technology Services, Inc. | 3 | $83 |
| Merck | 4 | $73 |
| Kowa Pharmaceuticals America, Inc. | 5 | $65 |
| AbbVie | 4 | $61 |
| Amarin Pharma, Inc. | 4 | $59 |
| AstraZeneca | 3 | $46 |
| Abiomed | 2 | $45 |
| Cardiva Medical, Inc. | 2 | $43 |
| Pfizer | 3 | $38 |
| Biocompatibles, Inc. | 2 | $30 |
| Itamar Medical Inc | 2 | $29 |
| Sanofi | 1 | $26 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Philips North America LLC | 1 | $16 |
| CMP Pharma, Inc. | 1 | $14 |
| Terumo Medical Corporation | 1 | $13 |
| Chiesi USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$76,612
- Indigo$4,350
- VenaCure 1470 Pro$993
- ClosureFast$769
- SUPERA$558
- Confirm Rx$473
- Barostim Neo System$415
- IN.PACT Admiral$406
- CARDIOMEMS$278
- SYMPLICITY G3$276
- Assurity Pacemaker$272
- PANTHERIS$241
- EMBOSHIELD NAV6$177
- WATCHMAN FLX$148
- Penumbra System$148
- UPTRAVI$125
- OPSUMIT$125
- XARELTO$125
- CAMZYOS$125
- Repatha$124
How this compares
$99,366 in reported general payments places this provider in the 80th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 250 | $239,029 |
| XareltoRivaroxaban | 224 | $202,707 |
| EntrestoSacubitril/Valsartan | 102 | $104,838 |
| JardianceEmpagliflozin | 41 | $34,166 |
| Repatha SureclickEvolocumab | 18 | $16,128 |
| Flecainide Acetate | 289 | $10,091 |
| VascepaIcosapent Ethyl | 11 | $9,518 |
| Rosuvastatin Calcium | 450 | $6,644 |
| Metoprolol Succinate | 589 | $5,373 |
| Ranolazine ErRanolazine | 35 | $4,822 |
| Spironolactone | 765 | $4,810 |
| ClopidogrelClopidogrel Bisulfate | 397 | $4,236 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 182 | $4,068 |
| Isosorbide Dinitrate | 98 | $3,562 |
| Midodrine Hcl | 67 | $3,134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $38 | $239,029250 claims |
| Johnson & JohnsonXarelto | $388 | $202,707224 claims |
| NovartisEntresto | $330 | $104,838102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Glendale
- Rahul MalhotraGlendale$103K
- Paul SorajjaPhoenix$8.8M
- Thomas WaggonerTucson$4.1M
- Hursh NaikAvondale$2.2M
- Nabil DibGilbert$2.2M
- Timothy ByrnePhoenix$2.1M
- Ashish PershadChandler$1.4M
- Mohamad LazkaniPhoenix$1.1M
- Parminder SinghPhoenix$854K
- Samuel ButmanCottonwood$706K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.